- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
London Co. of Virginia Sells 42,828 Shares of Johnson & Johnson
Firm reduces stake in pharmaceutical giant by 2.4% in Q3
Mar. 17, 2026 at 10:06am
Got story updates? Submit your updates here. ›
London Co. of Virginia, a major investment firm, has lowered its stake in Johnson & Johnson (NYSE: JNJ) by 2.4% during the third quarter, according to a recent SEC filing. The firm now owns 1,767,375 shares of the company's stock, down from 1,810,203 shares previously.
Why it matters
Johnson & Johnson is one of the world's largest and most influential pharmaceutical companies, so changes in major institutional investors' holdings can provide insights into market sentiment and potential shifts in the stock's performance.
The details
According to the filing, London Co. of Virginia sold 42,828 shares of Johnson & Johnson stock during the third quarter. The firm now owns approximately 1.8% of the company, making it Johnson & Johnson's 18th largest institutional shareholder. The sale represents a 2.4% reduction in London Co. of Virginia's total position in the stock.
- The share sale occurred during the third quarter of 2026.
The players
London Co. of Virginia
A major investment management firm that owns a significant stake in pharmaceutical giant Johnson & Johnson.
Johnson & Johnson
A multinational healthcare company that develops, manufactures, and markets a broad range of pharmaceutical, medical device, and consumer health products.
The takeaway
This transaction highlights the ongoing shifts in institutional ownership of Johnson & Johnson stock, which could signal broader market trends or changes in investor sentiment towards the company and the pharmaceutical industry as a whole.
